PROTAC Concept PROTACs has become a new model of drug discovery, with the potential to change traditional drug discovery, and may become a new blockbuster therapy. PROTACs is a bifunctional separator, whichRead More…
Nature: Development Directions of PROTAC Targeted Protein Degradation Technology in the Next 20 Years
It took nearly 20 years for PROTAC technology to transform from academia to preclinical and clinical drug development projects. In 2019, PROTAC obtained the clinical proof of concept in oncology for theRead More…
Cell: More han 100 Potential PROTAC Targets Revealed
There are about 514 different protein kinases operating in human cells, accounting for 2.5% of the entire human genome. For scientists who want to use targeted protein degradation (TPD) technology to destroyRead More…
PROTAC Therapy R&D: Obstacles and Solutions
The wide range of application and the great potential in overcoming drug resistance and targeting non-proprietary targets, research and development in PROTAC field has been hot in recent years. PROTAC, protein degradationRead More…
PROTAC “modified” molecular glue—MDM2 degrader can degrade p53
PROTACs, also named as Proteolysis-Targeting Chimeras, is a new type of drug that is different from antibodies and traditional small molecular inhibitors. It consists of target proteins ligand, linker, and E3 ubiquitinRead More…
Blockbuster: 1336 PROTAC targets revealed in Nature
PROTAC, proteolysis targeting chimera, or proteolytic targeted chimera, is a new type of drug different from antibodies and traditional small molecule inhibitors. PROTAC consists of target protein binder, linker, and E3 ubiquitinRead More…
A strategic partnership worthy of 2.45 billion dollars reached between Pfizer and Arvinas to develop PROTAC protein degradants against ER+ breast cancer!
Recently, Pfizer and Arvinas announced a partnership to develop and commercialize ARV-471, an oral PROTAC estrogen receptor protein degrader under development. Estrogen receptor (ER) is a well-known disease driver in most breastRead More…
Industrial Research Report of PROTAC-II
Main steps of PROTAC to achieve intracellular protein degradation To achieve intracellular protein degradation requires multiple steps, such as cellular uptake, effective recruitment of E3 ligase, ubiquitination of target proteins, and recruitmentRead More…
Industrial Research Report of PROTAC-I
In 2004, the Nobel Prize in Chemistry was awarded to Israeli scientists Aaron Sichanova, Afram Hershko and American scientist Irwin Ross for their discovery of ubiquitin-regulated protein degradation. Protein degradation is ratedRead More…
Times of PROTAC Explosion: Mechanism, Drugs, and 20-year Revolution
Recently, Pfizer and Arvinas jointly announced that they have reached an agreement to co-develop and promote the PROTAC protein degrader ARV-471. Arvinas will receive $650 million in upfront payments and potentially upRead More…